Abstract
At present, monopolistic acts are frequent in the active pharmaceutical ingredient (API) industry, which exerts a serious impact on the normal functioning of the API market and pharmaceutical market. This industry is closely bound up with numerous patients and is a major livelihood issue. Antitrust enforcement agencies have investigated seven API antitrust cases. Based on these seven cases, this article will compare the similarities and differences between the National Development and Reform Commission and the Administration for Industry & Commerce (AIC) in law enforcement approaches and analyze the advantages and defects of antitrust enforcement in the API industry in China.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
